BiotechTube

YM 155 + Docetaxel + Prednisone

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostate Cancer

Conditions

Prostate Cancer, Tumors

Trial Timeline

May 1, 2007 → Mar 1, 2010

NCT ID
NCT00514267

About YM 155 + Docetaxel + Prednisone

YM 155 + Docetaxel + Prednisone is a phase 1/2 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00514267. Target conditions include Prostate Cancer, Tumors.

What happened to similar drugs?

20 of 20 similar drugs in Prostate Cancer were approved

Approved (20) Terminated (4) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved
✅LeuprolideAstellas PharmaApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00514267Phase 1/2Completed

Competing Products

20 competing products in Prostate Cancer

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
18
PemetrexedEli LillyPhase 2
35
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
Abemaciclib + Placebo + Abiraterone acetate + PrednisoneEli LillyPhase 2/3
42
eFT508eFFECTOR TherapeuticsPhase 2
17
EnhertuDaiichi SankyoPhase 2
42
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
47
exatecan mesylateDaiichi SankyoPhase 2
35
PLX3397Daiichi SankyoPhase 2
27
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
29
degarelix + GoserelinAstellas PharmaPhase 3
40
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
26
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetateAstellas PharmaPhase 2
42